THCV Oral Strips Produced Significant Weight Loss and Metabolic Improvements Over 90 Days

THCV/CBD oral strips produced statistically significant weight loss, decreased abdominal girth, reduced systolic blood pressure, and lowered total and LDL cholesterol compared to placebo. The higher dose (16 mg THCV/20 mg CBD) was superior to the lower dose (8 mg THCV/10 mg CBD) for weight loss, and both differed significantly from placebo.

Placebo-controlled study of 44 subjects (31 females, 13 males, average age 51.75) evaluating two doses of THCV/CBD via mucoadhesive oral strips taken once daily for 90 days. Outcomes included weight, abdominal girth, blood pressure, and cholesterol.

THCV is a CB1 neutral antagonist, and this is among the first human trials testing whether its proposed metabolic effects translate to actual weight loss and metabolic improvements in a controlled setting.

The CB1 antagonist approach to weight loss was previously explored with rimonabant, which was withdrawn due to psychiatric side effects. THCV's neutral antagonism (rather than inverse agonism) may offer a safer profile, but much larger trials are needed to confirm both efficacy and safety.

Very small sample size (44 total, even smaller per group). No details on randomization or blinding methodology. Combined THCV with CBD, so individual contributions are unclear. 90-day follow-up does not address long-term sustainability. Limited demographic diversity.